MIA3 in Coronary Artery Disease ( CAD ): An In‐Depth Review of Its Role in Vascular Smooth Muscle Cell ( VSMC ) Homeostasis, Pathogenesis, and Its Therapeutic Potential
IUBMB Life · 2025
DOI: 10.1002/iub.70076 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift IUBMB Life, 2025. Verfasst von Yousuf Tahir Ali und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan. Hauptthemen laut MEDLINE: Coronary Artery Disease, Myocytes, Smooth Muscle, Aryl Hydrocarbon Receptor Nuclear Translocator, Atherosclerosis. Die Arbeit nennt 101 Literaturangaben.
Abstract (Originalsprache)
A significant portion of fatalities from coronary artery disease (CAD) has been attributed to be primarily triggered by atherosclerosis. The melanoma inhibitory activity protein‐3 ( MIA3 ) gene has been found to be a key regulator for plaque stability in coronary artery atherosclerosis. Recent advances have unveiled the role of this gene in the formation of MIA3 protein, via which it potentially regulates the homeostatic circuit of various molecular proteins inside the cell and provides a safety profile to heart patients. Understanding how this gene exists, functions, signals, and can be targeted is therefore crucial to tackle the challenges in the field of cardiology. In this review, we have elaborated on its role in various cellular processes and several reported diseases to develop a holistic insight into the function of this gene. We have shown how this gene contributes to the budding of vesicles from the endoplasmic reticulum and helps in the transport of apolipoproteins and collagen to the exterior of the cell. We shed light on its role in the pathogenesis of CAD and also explain its role in other diseases involving bone mineralization or collagen defects. We explore the MIA3 gene at both genetic and protein levels and elaborate on its evolutionary conservation across species. In this paper, we also dissect the signaling mechanisms of the MIA3 gene inside the cell involving several protein interactions to form the COPII complex and initiate the vesicular budding at the endoplasmic reticulum. We also discuss the various therapeutic options that can target the MIA3 signaling pathway in several diseases, with a particular emphasis on CAD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
- Institute for the Advanced Study of Human Biology (ASHBi), Graduate School of Medicine, Kyoto University, Kyoto, Japan.
- A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Finland.
- Institute for Cardiogenetics, University of Lübeck, Lübeck, Germany.
- DZHK (German Centre for Cardiovascular Research), Partner Site Hamburg/Kiel/Lübeck, Lübeck, Germany.
- University Heart Centre Lübeck, Lübeck, Germany.
ORCID-Profile: Yousuf Tahir Ali, Redouane Aherrahrou
Zitieren
APA
Ali, Y. T., Ravindran, A., Eichelmann, L., Odenthal, N., & Aherrahrou, R. (2025). MIA3 in Coronary Artery Disease ( CAD ): An In‐Depth Review of Its Role in Vascular Smooth Muscle Cell ( VSMC ) Homeostasis, Pathogenesis, and Its Therapeutic Potential. IUBMB Life. https://doi.org/10.1002/iub.70076
Vancouver
Ali YT, Ravindran A, Eichelmann L, Odenthal N, Aherrahrou R. MIA3 in Coronary Artery Disease ( CAD ): An In‐Depth Review of Its Role in Vascular Smooth Muscle Cell ( VSMC ) Homeostasis, Pathogenesis, and Its Therapeutic Potential. IUBMB Life. 2025. doi:10.1002/iub.70076
BibTeX
@article{Ali2025,
author = {Ali, Yousuf Tahir and Ravindran, Aarthi and Eichelmann, Luis and Odenthal, Nadine and Aherrahrou, Redouane},
title = {MIA3 in Coronary Artery Disease ( CAD ): An In‐Depth Review of Its Role in Vascular Smooth Muscle Cell ( VSMC ) Homeostasis, Pathogenesis, and Its Therapeutic Potential},
journal = {IUBMB Life},
year = {2025},
doi = {10.1002/iub.70076}
}
EUVIMED